Alphamab Oncology Presents Promising Efficacy Data for JSKN003 in Phase I and Phase II Clinical Trials

Strategic Insights -

JSKN003, a biparatopic anti-HER2 antibody-drug conjugate, has demonstrated promising efficacy in treating primary platinum-refractory ovarian cancer, HER2-positive metastatic colorectal cancer, and platinum-resistant ovarian cancer, according to data presented at the 2025 European Society for Medical Oncology Congress. The therapy showed a significant response rate, disease control rate, and overall survival rate in heavily pretreated patients.

Key Takeaways:

  • JSKN003 demonstrated an overall response rate (ORR) of 32.0% and disease control rate (DCR) of 72.0% in primary platinum-refractory ovarian cancer.
  • In HER2-positive metastatic colorectal cancer, JSKN003 showed an ORR of 68.8% and DCR of 96.9%, with a median duration of response (DoR) of 9.89 months.
  • The therapy was granted breakthrough therapy designation by the Chinese National Medical Products Administration (NMPA) for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
  • JSKN003-306, a Phase III clinical study, aims to further validate the superiority of JSKN003 over current therapies in platinum-resistant ovarian cancer.

Statistics:

  • 26 patients with primary platinum-refractory ovarian cancer were enrolled in the JSKN003-102 trial, with a median age of 54 years and 80.8% having ECOG PS 1.
  • 33 patients with HER2-positive metastatic colorectal cancer were enrolled in the JSKN003-102 trial, with a median age of 59 years and 69.7% being male.
  • The overall survival rate at 9 months was 65.4% in primary platinum-refractory ovarian cancer and 66.6% in HER2-positive metastatic colorectal cancer.
  • 46 patients with platinum-resistant ovarian cancer were enrolled in the JSKN003-306 trial, with a median age of 51 years and 85.2% having ECOG PS 1.

Sources:

  • Alphamab Oncology. (2025). JSKN003, a Biparatopic Anti-HER2 Antibody-Drug Conjugate (ADC), in the Treatment of Primary Platinum-Refractory Ovarian Cancer. 2025 European Society for Medical Oncology Congress.
  • Alphamab Oncology. (2025). Efficacy and Safety of JSKN003, a Biparatopic anti-HER2 Antibody Drug Conjugate (ADC), in Patients with HER2-positive Metastatic Colorectal Cancer (mCRC). 2025 European Society for Medical Oncology Congress.
  • Alphamab Oncology. (2025). Phase III Study of JSKN003, a Biparatopic Anti-HER2 Antibody-Drug Conjugate (ADC), versus Physician's Choice of Chemotherapy in Platinum-Resistant Ovarian Cancer (PROC): JSKN003-306. 2025 European Society for Medical Oncology Congress.